|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-8-20
|
|
pubmed:abstractText |
Despite the beneficial effect of imatinib treatment in chronic myeloid leukemia patients, some patients develop resistance and/or intolerance and need a switch to second-generation tyrosine kinase inhibitors. Dasatinib is indicated for chronic myeloid leukemia patients with resistance or intolerance to imatinib; it has 325-fold increase potency compared to imatinib and is active in mutated and unmutated resistant patients. Pleural/pericardic effusions are frequent complications during treatment with dasatinib, and usually are reported to require dose reduction or drug discontinuation. Changing the dasatinib regimen from 70 mg twice daily to 100 mg once daily reduces the risk of pleural effusions.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1744-764X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
713-21
|
|
pubmed:dateRevised |
2011-8-25
|
|
pubmed:meshHeading |
pubmed-meshheading:20722490-Aged,
pubmed-meshheading:20722490-Antineoplastic Agents,
pubmed-meshheading:20722490-Autoimmune Diseases,
pubmed-meshheading:20722490-Cardiovascular Diseases,
pubmed-meshheading:20722490-Clinical Trials as Topic,
pubmed-meshheading:20722490-Comorbidity,
pubmed-meshheading:20722490-Disease Management,
pubmed-meshheading:20722490-Drug Administration Schedule,
pubmed-meshheading:20722490-Drug Eruptions,
pubmed-meshheading:20722490-Humans,
pubmed-meshheading:20722490-Hypercholesterolemia,
pubmed-meshheading:20722490-Incidence,
pubmed-meshheading:20722490-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:20722490-Leukocyte Count,
pubmed-meshheading:20722490-Pericardial Effusion,
pubmed-meshheading:20722490-Piperazines,
pubmed-meshheading:20722490-Pleural Effusion,
pubmed-meshheading:20722490-Protein Kinase Inhibitors,
pubmed-meshheading:20722490-Pyrimidines,
pubmed-meshheading:20722490-Risk Factors,
pubmed-meshheading:20722490-Thiazoles,
pubmed-meshheading:20722490-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
|
|
pubmed:affiliation |
Sapienza University, Department of Cellular Biotechnologies and Hematology, Via Benevento 6, 00161, Rome, Italy. breccia@bce.uniroma1.it
|
|
pubmed:publicationType |
Journal Article,
Review
|
